Angion Biomedica Corp
Elicio Therapeutics is a clinical-stage biotechnology company focused on engineering cancer immunotherapies that harness the natural power of the immune system. Their targeted-delivery approach generates robust immune responses to activate and amplify cancer-fighting T cells, aiming to treat aggressive tumors. They develop next-generation vaccines, immunomodulators, and adjuvants built with their AMP platform, with a focus on pancreatic ductal adenocarcinoma (PDAC). The company is committed to advancing immunotherapy through expertise in materials science, immunology, and cancer therapy, and aims to define the future of immunotherapy to improve patient outcomes.
Industries
Nr. of Employees
small (1-50)
Angion Biomedica Corp
451 D Street, 5th Floor, Suite 501, Boston, MA 02210, USA
Patents
Products
Clinical-stage lymph node-targeted mKRAS therapeutic vaccine (KRAS-mutant solid tumors)
A lymph node–targeted peptide/subunit vaccine program designed to generate mKRAS-specific T cell responses for patients with KRAS-mutated solid tumors, developed through early-phase clinical studies.
Preclinical lymph node-targeted vaccines for mutant BRAF and mutant TP53
Preclinical peptide/subunit vaccine programs targeting mutant BRAF and mutant TP53 intended for gastrointestinal and other solid tumors, leveraging lymph node-targeted delivery and adjuvant technology.
Clinical-stage lymph node-targeted mKRAS therapeutic vaccine (KRAS-mutant solid tumors)
A lymph node–targeted peptide/subunit vaccine program designed to generate mKRAS-specific T cell responses for patients with KRAS-mutated solid tumors, developed through early-phase clinical studies.
Preclinical lymph node-targeted vaccines for mutant BRAF and mutant TP53
Preclinical peptide/subunit vaccine programs targeting mutant BRAF and mutant TP53 intended for gastrointestinal and other solid tumors, leveraging lymph node-targeted delivery and adjuvant technology.
Services
Case-by-case evaluation and potential provision of investigational products outside clinical trials when regulatory and ethical conditions are met; requires physician submission and compliance with regulatory approvals and safety reporting.
Collaborative agreements and clinical supply arrangements to support combination studies, clinical development, and broader platform use.
Sponsorship and operational support for early-phase oncology vaccine trials with translational biomarker endpoints and MRD-guided patient selection.
Case-by-case evaluation and potential provision of investigational products outside clinical trials when regulatory and ethical conditions are met; requires physician submission and compliance with regulatory approvals and safety reporting.
Collaborative agreements and clinical supply arrangements to support combination studies, clinical development, and broader platform use.
Sponsorship and operational support for early-phase oncology vaccine trials with translational biomarker endpoints and MRD-guided patient selection.
Expertise Areas
- Cancer vaccine development
- Lymphatic-targeted delivery engineering
- Translational immunology and biomarker analysis
- Clinical trial management for oncology therapeutics
Key Technologies
- Lymph node-targeted amphiphile delivery
- Peptide vaccines
- Protein subunit vaccines
- Lipid-conjugated molecular adjuvants
News & Updates
Discussing AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer.
Funding to support ongoing research and development efforts.
Discussing AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer.
Funding to support ongoing research and development efforts.
Discussing AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer.
Funding to support ongoing research and development efforts.
Discussing AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer.
Funding to support ongoing research and development efforts.